In Q3 2025, Tang Capital Management held 149 positions worth $2.3B. They initiated 6 new positions and exited 68. Their largest holding was TARS ($145.9M). Portfolio value grew +32.8% versus the prior quarter.
Frequently asked questions
What stocks did Tang Capital Management own in Q3 2025?
Tang Capital Management held 149 biotech stocks in their 13F portfolio in Q3 2025. Their top positions include TARS, GLPGF, AUPH, PTCT, MIRM. The full holdings table is available on BiotechEdge with position sizes, quarter-over-quarter changes, and AI analysis.
How much was Tang Capital Management's portfolio worth in Q3 2025?
Tang Capital Management's tracked biotech portfolio was worth $2.3B across 149 positions, with total assets under management of approximately $2B. Portfolio values are based on 13F filings with the SEC.
What did Tang Capital Management buy in Q3 2025?
Tang Capital Management initiated 6 new positions in Q3 2025, including CELC, IDYA, PMVP, VOR, GHRS and 1 more. They also increased 26 existing positions.
What did Tang Capital Management sell in Q3 2025?
Tang Capital Management fully exited 68 positions in Q3 2025, including AMZN, TRVI, TNGX, STEL, SFBS and 63 more. They also trimmed 21 existing positions.
Is Tang Capital Management a biotech fund?
Event-driven biotech specialist known for concentrated bets around clinical catalysts, M&A situations, and activist campaigns. Deep industry relationships and willingness to engage publicly make the fund a closely watched market signal.
Want AI analysis, insider signals, and catalyst overlays for Tang Capital Management?
View latest Tang Capital Managementportfolio →